

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>A61K 47/02, 47/26, 31/47</b>	<b>A1</b>	(11) International Publication Number: <b>WO 99/62560</b> (43) International Publication Date: 9 December 1999 (09.12.99)
<p>(21) International Application Number: PCT/US99/10189</p> <p>(22) International Filing Date: 10 May 1999 (10.05.99)</p> <p>(30) Priority Data: 60/088,280 5 June 1998 (05.06.98) US</p> <p>(71) Applicant (for all designated States except US): WARNER-LAMBERT COMPANY [US/US]; 201 Tabor Road, Morris Plains, NJ 07950 (US).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): DANIEL, Jane, Ellen [US/US]; 1 Claridge Drive, Verona, NJ 07044 (US). HAR- RIS, Michael, Ray [US/US]; 178 College View Drive, Hackettstown, NJ 07840 (US). HOKANSON, Gerard, Clif- ford [US/US]; 1 Hunter Drive, Long Valley, NJ 07853 (US). WEISS, Jay [US/US]; 63 Independence Drive, East Brunswick, NJ 08810 (US).</p> <p>(74) Agents: RYAN, M., Andrea; Warner-Lambert Company, 201 Tabor Road, Morris Plains, NJ 07950 (US) et al.</p>		<p>(81) Designated States: AE, AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p><b>Published</b> <i>With international search report.</i></p>
<p>(54) Title: STABILIZATION OF COMPOSITIONS CONTAINING ACE INHIBITORS USING MAGNESIUM OXIDE</p> <p>(57) Abstract</p> <p>The present invention is directed to ACE inhibitor-containing compositions stabilized by the presence of magnesium oxide. Preferably, the ACE inhibitor, quinapril, is protected from certain forms of degradation when prepared in a pharmaceutical composition consisting essentially of magnesium oxide as the stabilizing agent. The presence of magnesium oxide also lends itself to favorable processing conditions during the manufacture of ACE inhibitor-containing compositions, especially processing by wet granulation.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## STABILIZATION OF COMPOSITIONS CONTAINING ACE INHIBITORS USING MAGNESIUM OXIDE

## FIELD OF THE INVENTION

The present invention is directed to ACE inhibitor-containing compositions stabilized by the presence of magnesium oxide. Preferably, the ACE inhibitor, quinapril, is protected from certain forms of degradation when prepared in a pharmaceutical composition consisting essentially of magnesium oxide as the stabilizing agent. The presence of magnesium oxide also lends itself to favorable processing conditions during the manufacture of ACE inhibitor-containing compositions, especially processing by wet granulation.

## BACKGROUND OF THE INVENTION

Certain ACE (Angiotensin Converting Enzyme) inhibitors, which are useful as antihypertensives, are susceptible to certain types of degradation. Specifically, quinapril and structurally-related drugs can degrade via (1) cyclization via internal nucleophilic attack to form substituted diketopiperazines, (2) hydrolysis of the side-chain ester group, and (3) oxidation to form products having often unwanted coloration.

U.S. Patent No. 4,743,450 discloses that stable compositions containing ACE inhibitors of the type discussed above can be produced using certain additives as stabilizers. Specifically, this patent discloses that the inorganic salts of metals of Group I and II of the Periodic Table act as stabilizers of ACE inhibitor-containing formulations susceptible to certain types of degradation. Magnesium carbonate is taught to be a preferred stabilizer.

One ACE inhibitor, quinapril HCl, is sold commercially under the tradename, ACCUPRIL®, and employs magnesium carbonate hydroxide in its formulations. Magnesium carbonate hydroxide contains approximately 40% to 42% magnesium oxide.

-2-

While magnesium carbonate hydroxide acts as an effective stabilizer of quinapril, its use in pharmaceutical formulations represents certain disadvantages. Magnesium carbonate hydroxide is a white, bulky powder which is difficult to formulate into tablets because of its poor compressibility, moldability, and flowability. The difficulties encountered by the use of magnesium carbonate hydroxide to formulate ACE inhibitor-containing compositions is accentuated when the compositions are manufactured using a wet granulation process.

The preparation of granulations for tableting by wet granulation is the oldest and still the most widely used. Before dry compaction became a viable process, wet granulation was - for all practical purposes - the only method available. However, it is laborious, involving considerable material handling, as well as several processing steps, and therefore it is costly. In general, the technique involves no more than the incorporation of a granulating fluid into the mixed, powdery tablet ingredients (including at least some tableting aids) in such an amount and manner as to convert them into a uniform, moist, coherent, non-pasty mass, which then is formed into moist granules of fairly uniform size, usually by forcing the mass through a screen. Thereafter, the moist granules are dried and rescreened to break down agglomerates, and finally blended with other tableting aids so as thus to arrive at the granulation ready for tableting.

It will be noted that in wet granulation, the tablet ingredients besides the active matter also conventionally include other, pharmacologically inert materials, certainly tableting aids and perhaps also bulking agents. Some of such tableting aids may be included in the mixed, powdery ingredients before the granulating fluid is incorporated therein, while further tableting aids may be applied to the surfaces of the granules, and in between them, after the granules have been formed and before the granulate is passed to the tableting machine.

The labor and cost so characteristic of wet granulation processes are common when compounds like magnesium carbonate hydroxide are mixed with ACE inhibitors like quinapril HCl. Manufacturers have experienced several rate-limiting steps when processing magnesium carbonate hydroxide: batch sizes limited due to the lower density of magnesium carbonate hydroxide blends; granulation times of 15 minutes or longer; variability in granulation times of 15 to

37 minutes when using different lots of magnesium carbonate hydroxide; need for high amounts of water to achieve granulation end points and potentially long drying times based upon initial loss on drying in the range of 23 to 29% (loss on drying or "LOD" is a moisture determination test using heat to determine how much water or solvent is in a product); and limitations in flowability.

Magnesium carbonate hydroxide is also problematic to manufacturers because of sourcing concerns.

It can be understood that it would be an improvement to the art if one could improve the wet granulation processing conditions of an ACE inhibitor-containing formulation without sacrificing the stabilizing effects of a compound like magnesium carbonate hydroxide.

#### SUMMARY OF THE INVENTION

It has been discovered that stable compositions containing ACE inhibitors of the type discussed above can be produced using magnesium oxide as the primary cyclization stabilizer. In one embodiment, a pharmaceutical composition is prepared by combining the ACE inhibitor, quinapril HCl, with a stabilizing agent consisting essentially of magnesium oxide. Use of magnesium oxide not only minimizes the cyclization degradation of ACE inhibitors, but also improves the formulation of ACE inhibitors into pharmaceutical compositions by the wet granulation technique. In a preferred embodiment, a pharmaceutical composition is prepared by combining the ACE inhibitor with not only a stabilizing agent consisting essentially of magnesium oxide, but also an agent that minimizes the hydrolysis of the ACE inhibitor, such as a saccharide, a diuretic, dicalcium phosphate or commonly known fillers having hydrolysis minimizing effects on the ACE inhibitor. In a more preferred, a pharmaceutical composition is prepared by combining 5.8 % by weight of magnesium oxide with 5.8 % weight of quinapril hydrochloride with the inclusion of 88.3 % weight of lactose to yield a composition which withstands oxidative, hydrolytic, and cyclization degradation at 60°C for 10 days.

In another embodiment, a process is disclosed for preparing stabilized ACE inhibitor-containing compositions with magnesium oxide. The process comprises the steps of contacting the ACE inhibitor with a suitable amount of a stabilizer consisting essentially of magnesium oxide and one or more hydrolysis-minimizing agents, such as saccharides, to minimize hydrolysis. In a preferred embodiment, the process comprises the steps of contacting quinapril HCl with a suitable amount of a stabilizer consisting essentially of magnesium oxide and one or more saccharides to form a mixture; and subjecting the mixture to wet granulation processing.

The compositions of the invention have several advantages over compositions which do not contain the stabilizing additive. Principally, the active ingredients or drugs contained therein are virtually protected from cyclization and hydrolysis. In addition, the discoloration which sometimes occurs when ACE inhibitors of this class are formulated and allowed to stand for significant periods of time is minimized or eliminated completely. Thus, a stable tableted quinapril formulation can be produced which will undergo no detectable oxidative discoloration.

In addition to having greater storage stability, the formulations of the present inventions are rendered more suitable for use in drug combinations.

The instant formulations are further advantageous due to the fact that the presence of magnesium carbonate hydroxide, and all of its inherent disadvantages, is unnecessary. Preparation of ACE inhibitor-containing compositions with magnesium oxide as the principal stabilizer results in improved processing by a wet granulation technique. Improvements that decrease the cost and labor include, but are not limited to an increase in batch sizes due to the high density of magnesium oxide formulations; granulation times of 4.5 to 5 minutes or less; decreased variability in granulation times (between 0.5 to 1 minute) when using different lots of magnesium oxide; decreased amounts of water to achieve granulation end points and shorter drying times based upon initial loss on drying (LOD) values in the range of 5% to 8% and improved flowability.

These and other advantages of the invention will become apparent from a consideration of the following description of the invention.

## DETAILED DESCRIPTION OF THE INVENTION

The invention deals with:


- I. A pharmaceutical composition which contains:
  - (a) an effective amount of a drug component which comprises an ACE inhibitor which is susceptible to cyclization, hydrolysis, and/or discoloration, and
  - (b) an effective amount of magnesium oxide and a hydrolysis-minimizing agent suitable to retard cyclization, hydrolysis, and/or discoloration, wherein the magnesium oxide is the principal cyclization stabilizer component of the composition.
- II. A process for stabilizing an ACE inhibitor drug which comprises the step of contacting the drug with:
  - (a) an effective amount of magnesium oxide and a hydrolysis-minimizing agent suitable to retard cyclization, hydrolysis, and/or discoloration, wherein the magnesium oxide is the principal cyclization stabilizer component of the composition.
- III. A method of making a pharmaceutical dosage form which comprises the step of including in the formulation suitable amounts of:
  - (a) an ACE inhibitor, and
  - (b) magnesium oxide and a hydrolysis-minimizing agent to retard cyclization, hydrolysis, and/or discoloration of the dosage form, the magnesium oxide acting as the principal cyclization stabilizer component of the dosage form.

Preferably, the compositions and processes made and used in accordance with the invention will also contain one or more substances which do not interfere with the function of the stabilizing additive(s). Generally, lubricants, such as magnesium stearate, hydrogenated vegetable oils and talc, binders, such as gelatin, and/or disintegrants, such as polyplasdone, are suitable.

## DRUG COMPONENT(S)

The compositions of the invention contain at least one ACE inhibitor and, optionally, one or more other medicament drugs or beneficial substances. The ACE inhibitors which can be used in the invention are any of a group of well-known compounds which have antihypertensive properties.

One preferred group of compounds includes compounds conforming to the general formula:



wherein A is absent, a fused 5-, 6-, or 7-membered cycloaliphatic ring or a fused benzene ring which is unsubstituted or substituted by 1 or 2 alkoxy groups having 1 to 4 carbon atoms; n is 0 or 1, and R is hydrogen or alkyl having 1 to 5 carbon atoms. Preferably A is absent, a fused 5- or 6-membered cycloaliphatic ring or a fused benzene ring which is unsubstituted or substituted by 2 methoxy groups; n is 0 or 1, and R is hydrogen or ethyl.

Particularly valuable are enalapril, quinapril, or indolapril, their corresponding free acids or pharmaceutically acceptable acid addition or base salts thereof. Compounds of this type are disclosed in U.S. Patent Nos. 4,344,949, 4,374,829, and 4,425,355, the disclosure of which are hereby incorporated by reference.

The total drug content of the final composition will be about 1% to about 70%, preferably from about 1% to about 25%, and most preferably from about 5% to about 8%.

All percentages stated herein are weight percentages based on total composition weight, unless otherwise stated.



The daily dosages of the pharmaceutical preparations of the invention depend upon the nature of the dosage form, the nature of the drug(s), and the type and extent of any interactive(s) in drug combinations. Thus, the therapeutic needs of the individual patient and the desires of the prescribing physician dictate the dosage levels to be employed. In general, however, the manufacturer's specifications for any drug or drug combination are useful guides to administration. *The Physicians' Desk Reference* or other suitable publication can be consulted to ascertain appropriate dosage levels.

Nonetheless, typical dosage levels for quinapril and enalapril are from about 1 mg to about 80 mg per dosage.

Suitable categories of drugs that may be employed in addition to ACE inhibitors in the instant compositions may vary widely and generally represent any stable drug combination. Illustrative categories and specific examples include:

- (a) Diuretics, such as hydrochlorothiazide,
- (b) Antitussives, such as dextromethorphan, dextromethorphan hydrobromide, noscapine, carbetapentane citrate, and chlophedianol hydrochloride,
- (c) Antihistamines, such as chlorpheniramine maleate, phenindamine tartrate, pyrilamine maleate, doxylamine succinate, and phenyltoloxamine citrate,
- (d) Decongestants, such as phenylephedrine hydrochloride, phenylpropanolamine hydrochloride, pseudoephedrine hydrochloride, and ephedrine,
- (e) Various alkaloids, such as codeine phosphate, codeine sulfate, and morphine,
- (f) Mineral supplements such as potassium chloride and the like.

The medicaments and/or other beneficial substances to be used herein may be selected from a wide variety of substances and pharmaceutically acceptable forms thereof, e.g., their acid addition salts. Both organic and inorganic salts may be used provided the drug maintains its medicament value. Exemplary acid salts include, but are not limited to, hydrochloride, hydrobromide, orthophosphate,

benzoate, maleate, tartrate, succinate, citrate, salicylate, sulfate, acetate, and the like. Mixtures are operable.

One preferred group of drugs to be used in combination with ACE inhibitors includes: betablockers, diuretics, calcium blockers, and the like.

5

#### STABILIZER(S)

10

The cyclization and hydrolytic instability which are exhibited by certain of the drugs discussed above can be overcome via the use of a suitable quantity, i.e., an effective amount of magnesium oxide together with an agent that minimizes the hydrolysis of the ACE inhibitor, such as saccharides. While additional stabilizers may be present in the present invention, their cyclization stabilizing effects on the ACE inhibitor formulations are minimal in comparison to the stabilizing effects of the magnesium oxide. Even small amounts of magnesium carbonate, which can result from the exposure of magnesium oxide to water and air, will have a minimal stabilizing effect on the ACE inhibitor formulations when compared to the stabilizing effect of the magnesium oxide present in the formulation.

15

Magnesium oxide, or calcined magnesia, is commercially available from such companies as Dead Sea Periclase of Israel, Lohmann of Germany or Morton International. This compound occurs in nature as the mineral periclase.

20

Commercial preparation of magnesium oxide from magnesite ores is described in U.S. Patent No. 3,320,029.

Magnesium oxide is available in many commercial grades, all of which are within the scope of the present invention. Two preferred forms of magnesium oxide are a very bulky form termed "Light" and a dense form termed "Heavy."

25

In the preferred embodiment of the invention, the stabilized ACE-inhibitor compositions consist essentially of magnesium oxide as the cyclization stabilizer. The quantity of the magnesium oxide to be used will lie between about 1% and 90%, preferably about 1% to about 50%, and most preferably about 1% to about

10% of the total composition. In general, any amount which will effectively retard or prevent cyclization degradation of the ACE inhibitor component(s) can be used.

### HYDROLYSIS-MINIMIZING AGENT

5 The hydrolysis-minimizing agents of the present invention act to protect the ACE inhibitor from hydrolytic degradation. The hydrolysis-minimizing agent(s) to be used in the pharmaceutical products and methods of the invention are substances which are compatible with magnesium oxide so that they do not interfere with magnesium oxide's function in the composition. Generally, they are substances which do not contain groups which could significantly interfere with  
10 the function of either the metal-containing component or the drug component. Preferred hydrolysis-minimizing agents of the present invention are saccharides such as mannitol, lactose, and other sugars, diuretics, dicalcium phosphate, hydrochloro thiazide, and known fillers that have a hydrolysis-minimizing effect on the ACE inhibitors. Saccharides are most preferred and mixtures are operable.

15 Generally, the quantity of the hydrolysis-minimizing agent present will be from about 10% to about 95%, preferably about 50% to about 95%, and most preferably from about 70% to about 90% of the total composition.

### DOSAGE FORMS

20 The compositions of the present invention can be administered to a patient alone or as part of a composition that contains other components such as excipients, diluents, and carriers, all of which are well-known in the art. The compositions can be administered to humans and animals either orally, rectally, parenterally (intravenously, intramuscularly, or subcutaneously), intracisternally, intravaginally, intraperitoneally, intravesically, locally (powders, ointments, or  
25 drops), or as a buccal or nasal spray.

The final form of the pharmaceutical preparations made in accordance with the invention can vary greatly. Orally administrable forms, i.e., tablets, caplets,

and capsules, are preferred. Solid, semi-solid, and liquid formulations can be made. However, solids are highly preferred. The optional excipients which can be used in the instant compositions are also substances which must be compatible with magnesium oxide so that it does not interfere with its function in the composition.

Compositions suitable for parenteral injection may comprise physiologically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions, or emulsions and sterile powders for reconstitution into sterile injectable solutions or dispersions. Examples of suitable aqueous and nonaqueous carriers, diluents, solvents, or vehicles include water, ethanol, polyols (propyleneglycol, polyethyleneglycol, glycerol, and the like), Cremophor EL (a derivative of castor oil and ethylene oxide; purchased from Sigma Chemical Co., St. Louis, MO) and suitable mixtures thereof, vegetable oils (such as olive oil), and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.

These compositions may also contain adjuvants such as preserving, wetting, emulsifying, and dispensing agents. Prevention of the action of microorganisms can be ensured by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, and the like. It may also be desirable to include isotonic agents, for example sugars, sodium chloride, and the like. Prolonged absorption of the injectable pharmaceutical form can be brought about by the use of agents delaying absorption, for example, aluminum monostearate and gelatin.

Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is admixed with at least one inert customary excipient (or carrier) such as sodium citrate or dicalcium phosphate or (a) fillers or extenders, as for example, starches, lactose, sucrose, glucose, mannitol, and silicic acid; (b) binders, as for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose, and acacia; (c) humectants, as for example, glycerol; (d) disintegrating agents, as for

example, agar-agar, potato or tapioca starch, alginic acid, certain complex silicates, modified starch, polyvinylpyrrolidone (cross- or uncross-linked), and modified cellulose derivatives, (e) solution retarders, as for example paraffin; (f) absorption accelerators, as for example, quaternary ammonium compounds; (g) wetting agents, as for example, cetyl alcohol and glycerol monostearate; (h) adsorbents, as for example, kaolin and bentonite; (i) lubricants, as for example, talc, hydrogenated vegetable oil, zinc stearate, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate; (j) pigments; and (k) colorants or mixtures thereof. In the case of capsules, tablets, and pills, the dosage forms may also comprise buffering agents.

Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethyleneglycols and the like.

Solid dosage forms such as tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells, such as enteric coatings and others well-known in the art. They may contain opacifying agents, and can also be of such composition that they release the active compound or compounds in a certain part of the intestinal tract in a delayed manner. Examples of embedding compositions which can be used are polymeric substances and waxes. The active compounds can also be in micro-encapsulated form, if appropriate, with one or more of the above-mentioned excipients.

Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art, such as water or other solvents, solubilizing agents and emulsifiers, as for example, ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propyleneglycol, 1,3-butyleneglycol, dimethylformamide, oils, in particular, cottonseed oil, groundnut oil, corn germ oil, olive oil, castor oil and sesame oil, glycerol, tetrahydrofurfuryl alcohol, Cremophor EL (a derivative of castor oil and ethylene oxide; purchased from Sigma Chemical Co., St. Louis, MO), polyethyleneglycols and fatty acid esters of sorbitan or mixtures of these substances, and the like.

Besides such inert diluents, the composition can also include adjuvants, such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents. Suspensions, in addition to the active compounds, may contain suspending agents, as for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, or mixtures of these substances, and the like.

Compositions for rectal administrations are preferably suppositories which can be prepared by mixing the compounds of the present invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol, or a suppository wax, which are solid at ordinary temperatures but liquid at body temperature and, therefore, melt in the rectum or vaginal cavity and release the active component.

Dosage forms for topical administration of a compound of this invention include ointments, powders, sprays, and inhalants. The active component is admixed under sterile conditions with a physiologically acceptable carrier and any preservatives, buffers, or propellants as may be required. Ophthalmic formulations, eye ointments, powders, and solutions are also contemplated as being within the scope of this invention.

The above ACE inhibitor-containing compositions set forth above will be used in therapeutic amounts as indicated in the Physicians' Desk Reference (PDR) 47<sup>th</sup> Edition (1993), which is incorporated herein by reference, or such therapeutically useful amounts as would be known to one of ordinary skill in the art.

The compositions can be administered at the recommended maximum clinical dosage or at lower doses. Dosage levels of the active compounds in the compositions of the invention may be varied so as to obtain a desired therapeutic response depending on the route of administration, severity of the disease, and the response of the patient. The determination of optimum dosages for a particular patient is well known to those skilled in the art.

## PROCESSING

The present invention is directed to a process for stabilizing an ACE inhibitor drug which comprises the step of contacting an effective amount of the drug with an effective amount of magnesium oxide and a hydrolysis-minimizing agent suitable to retard cyclization, hydrolysis, and/or discoloration, wherein the magnesium oxide is the principal cyclization stabilizer component of the composition. While any techniques known to those of skill in the art for contacting the drug and the magnesium oxide, and which are appropriate, can be employed, a wet granulation process is preferred. The presence of magnesium oxide lends itself to improved wet granulation processing of ACE inhibitor-containing compositions, the advantages of which are discussed below in detail in Example 6 where a comparison is made of previously known magnesium carbonate hydroxide formulations and the magnesium oxide formulations of the present invention. A summary of these advantages is as follows:

- (1) magnesium oxide formulations are dense and can allow an increase in batch sizes using current equipment;
- (2) a decrease in granulation times, the granulation times ranging from about 4.5 to about 5 minutes or less;
- (3) a decrease in the variability in granulation times, the variability ranging from about 0.5 to about 1 minute when using different lots of magnesium oxide;
- (4) a decrease in the amounts of water required to achieve granulation end points and potentially shorter drying times, the amounts of water required is from about 50% or less and drying times of about 7 minutes;
- (5) initial LODs in the range of 5 to 8%;
- (6) an improvement in the flowability or angle of repose test where magnesium oxide formulations had a flowability or angle of repose of 32°.

In a preferred embodiment, the present invention is directed to a process for preparing a stabilized pharmaceutical composition comprising an effective

amount of an ACE inhibitor and a hydrolysis-minimizing agent and consisting essentially of an effective amount of magnesium oxide as the cyclization stabilizing agent, wherein the process comprises:

- (1) blending together a suitable amount of an ACE inhibitor, a hydrolysis-minimizing agent and magnesium oxide;
- (2) adding a granulating fluid to the blend to form a moist mass;
- (3) drying the granules; and
- (4) blending the granules with pharmaceutically inactive excipients.

The process further comprises the optional steps of screening the dried granules before addition of the pharmaceutically inactive excipients. The granulation medicament so formed may then be subjected to further conventional processing to form various solid dosage forms. The solid dosage forms may then be processed into final dosage forms by conventional techniques.

The percentages in which excipients are used are not critical. In general, their quantities will be consistent with the amount given above for the drug and stabilizer components (disintegrant about 1% to about 15% of the total composition; lubricant about 0.1% to about 5% of the total composition; and binder about 1% to about 10% of the total composition), i.e., they make up the remainder of the composition.

The drug preparations can be adapted for immediate, slow, or sustained release profiles, or any combination of these. Thus, a formulation adapted to give an initial loading dosage within 30 minutes followed by sustained release of the remaining drug over 4 to 12 hours is contemplated. Sustained and immediate release formulations are preferred. Reasonable variations, such as those which would occur to a skilled artisan, can be made herein without departing from the scope of the invention.

The examples presented below are intended to illustrate particular embodiments of the invention, and are not intended to limit the scope of the specification or the claims in any way.



-15-

## EXAMPLE 1

The following materials were processed by wet granulation method for the manufacture of 20-mg tablets.

Quinapril Hydrochloride	21.7 mg
Magnesium Oxide	21.7 mg
Lactose	254.3 mg
Gelatin	6.4 mg
Polyplasdone	12.8 mg
Magnesium Stearate	3.2 mg

## EXAMPLE 2

5 The following materials were processed by wet granulation for the manufacture of 5-mg tablets without the addition of a stabilizer.

Quinapril Hydrochloride	5.425 g
Lactose Anhydrous	119.575 g
Microcrystalline Cellulose	14.775 g
Disodium EDTA	0.225 g
Sterotex HM	1.500 g
Syloid 244 Silica Gel	3.000 g
Stearic Acid	4.500 g
Ascorbic Acid USP	1.000 g
Water, Purified USP	2.250 g

## EXAMPLE 3

The following materials were processed by wet granulation for the manufacture of 20-mg tablets without the addition of a stabilizer of the present invention.

-16-

Quinapril Hydrochloride	21.7 mg
Magnesium Carbonate Hydroxide	125.0 mg
Lactose	33.3 mg
Gelatin	10.0 mg
Polyplasdone	8.0 mg
Magnesium Stearate	2.0 mg

## EXAMPLE 4

Stability of the tablets prepared in Examples 1 and 3 were tested at 60°C for 10 days. The data shows that the use of magnesium oxide effectively stabilizes ACE inhibitor-containing compositions such as quinapril HCl compositions when compared against similar formulations that do not contain a stabilizer (Example 2) or contain magnesium carbonate hydroxide (Example 3). The data not only shows that magnesium oxide stabilizes ACE inhibitor-containing compositions as well as magnesium carbonate hydroxide, but also that the magnesium oxide formulation requires less gelatin (about 2%) than the magnesium carbonate hydroxide formulation (about 5%) to obtain acceptable compressability.

	Quinapril (%) Initial/10 Days	Degradation Products (%)	
		Diketopiperazine	Hydrolysis Product
Example 1	98.7/98.9	--	--
Example 2 <sup>a,b</sup>	68.1	32.4	<1
Example 3	97.7/96.1	--	--

<sup>a</sup> Percent of original quinapril content

<sup>b</sup> Analysis was carried out after 1 month at 60°C.

## EXAMPLE 5

Quinapril formulations containing magnesium oxide and quinapril formulations containing magnesium carbonate hydroxide were prepared for

-17-

comparison in wet granulation processing. The formulations (1.5 kgs MgO and 1.5 kgs MgCO<sub>3</sub>) were prepared by combining the following ingredients:

Quinapril HCl	162.5g	101.7g
Magnesium Oxide	--	101.7g
Magnesium Carbonate Hydroxide	937.5g	--
Lactose	250.0g	1191.6g
Gelatin	75.0g	30.0g
Polyplasdone	60.0g	60.0g
Magnesium Stearate	15.0g	15.0g

#### Results

- 5     • The magnesium oxide formulations were denser than the magnesium carbonate hydroxide formulations. 2.5 kgs of the magnesium oxide formulations were able to be granulated in a 10 L Gral when compared to 1.5 kgs of magnesium carbonate hydroxide formulations. The bulk density of the blends prior to the addition of the gelatin solution was 0.70 g/mL for  
10     quinapril/magnesium oxide and 0.27 g/mL for quinapril/magnesium carbonate hydroxide.
- The granulation time was shorter (4.5 to 5 minutes) with the magnesium oxide formulations compared to magnesium carbonate hydroxide formulations (15 to 37 minutes).
- 15     • The variability in granulation times was decreased; about 15 to 17 minutes using different lots of magnesium carbonate hydroxide and 0.5 to 1 minute using different lots of magnesium oxide.
- The quantity of water used to achieve granulation end point was decreased; magnesium oxide used 50% less water than magnesium carbonate hydroxide  
20     formulations.

-18-

- The initial LOD for the magnesium oxide formulations was in the range of 5% to 8% compared to 23% to 29% for the magnesium carbonate hydroxide formulations.
- 5 • The magnesium oxide formulations dried faster (7 minutes) than the magnesium carbonate hydroxide formulations (15-18 minutes).
- A second wet milling step was avoided in the magnesium oxide formulations because no lumps with moisture in them were observed unlike the magnesium carbonate hydroxide formulations.
- 10 • The flowability or angle of repose test indicated that the magnesium oxide formulations had better flowability (32°angle of repose) than the magnesium carbonate formulations (35°angle of repose).
- Only one formulation containing magnesium oxide was necessary to deliver or manufacture quinapril HCl in four strengths (5, 10, 20 and 40 mg) compared to the two formulations required to deliver quinapril HCl in 5/10 mg and 20/40  
15 mg strengths.


## CLAIMS

What is claimed is:

1. A pharmaceutical composition which contains:
  - 5 (a) a drug component which comprises a suitable amount of an ACE inhibitor which is susceptible to cyclization, hydrolysis, and discoloration,
  - (b) a suitable amount of a stabilizer to retard cyclization and discoloration, the stabilizer consisting essentially of magnesium oxide, and
  - 10 (c) a suitable amount of a hydrolysis-minimizing agent to inhibit hydrolysis.
2. The composition of Claim 1 wherein (a) is quinapril or a pharmaceutically acceptable acid addition salt thereof.
3. The composition of Claim 1 wherein (a) contains at least one additional  
15 drug.
4. The composition of Claim 1 wherein magnesium oxide is the only alkaline earth metal salt present in the composition.
5. The composition of Claim 1 wherein (b) contains about 1% to about 90% magnesium oxide per total weight of the formulation.
- 20 6. The composition of Claim 1 wherein (c) contains at least one of mannitol and lactose.
7. The composition of Claim 1 wherein the composition also contains at least one material selected from the group consisting of: binders, disintegrants, and lubricants.

-20-

8. The composition of Claim 1 wherein the hydrolysis-minimizing agent is a saccharide.
9. A pharmaceutical composition which contains: (a) is a compound of Formula I



wherein A is absent, a fused 5-, 6-, or 7-membered cycloaliphatic ring or a fused benzene ring which is unsubstituted or substituted by 1 or 2 alkoxy groups having 1 to 4 carbon atoms; n is 0 or 1, and R is hydrogen or alkyl having 1 to 5 carbon atoms, or a pharmaceutically acceptable acid addition salt thereof; (b) a suitable amount of a stabilizer to retard cyclization and discoloration, the stabilizer consisting essentially of magnesium oxide; and (c) a suitable amount of a saccharide to inhibit hydrolysis.

10. The composition of Claim 9 wherein A is absent, a fused 5- or 6-membered cycloaliphatic ring or a fused benzene ring which is unsubstituted or substituted by 2 methoxy groups; n is 0 or 1, and R is hydrogen or ethyl, or a pharmaceutically acceptable acid addition salt thereof.

11. The composition of Claim 9 wherein (a) is quinapril hydrochloride.

12. A tablet containing the composition of Claim 1.

13. A tablet containing the composition of Claim 11.

14. A process for stabilizing an ACE inhibitor drug against cyclization which comprises the step of contacting the drug with:

-21-

- (a) a suitable amount of magnesium oxide to retard cyclization, wherein the magnesium oxide is the principal stabilizer, and
- (b) one or more saccharides.

5        15.    The process of Claim 14 wherein the drug is selected from the group consisting of quinapril, enalapril, and indolapril, or a pharmaceutically acceptable acid addition salt thereof.

10       16.    The process of Claim 14 wherein the process further comprises the steps of:  
blending together a suitable amount of an ACE inhibitor, a hydrolysis-minimizing agent and magnesium oxide;  
adding a granulating fluid to the blend to form a moist mass;  
drying the granules; and  
blending the granules with pharmaceutically inactive excipients.

15       17.    The process of Claim 16 wherein the process further comprises the steps of:  
screening the dried granules once before addition of the pharmaceutically inactive excipients.

# INTERNATIONAL SEARCH REPORT

National Application No  
PCT/US 99/10189

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K47/02 A61K47/26 A61K31/47

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 4 743 450 A (HARRIS MICHAEL ET AL) 10 May 1988 (1988-05-10) cited in the application abstract column 1, line 1 - line 22 column 2, line 32 - line 34 column 3, line 25 - line 44 examples A-E claims 1-17	1-17
A	US 4 793 998 A (MURTHY KUCHI S ET AL) 27 December 1988 (1988-12-27) abstract column 1, line 20 - line 35 column 4, line 30 - line 59 examples 1-3 claims 1-21	1-17

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

27 August 1999

Date of mailing of the international search report

03/09/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Taylor, G.M.



# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/10189

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>US 4 830 853 A (MURTHY KUCHI S ET AL)  16 May 1989 (1989-05-16)  abstract  column 1, line 13 - line 26  column 3, line 41 - column 46  example 1  claims 1-21</p>	1-17
A	<p>EP 0 468 929 A (SANDOZ LTD)  29 January 1992 (1992-01-29)  abstract  page 2, line 1 - line 49  example 1  claims 1-16</p>	1-17

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/10189

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4743450 A	10-05-1988	AT 84210 T	15-01-1993
		AU 597471 B	31-05-1990
		AU 1130588 A	25-08-1988
		CA 1300510 A	12-05-1992
		DE 3877226 A	18-02-1993
		DK 94088 A	25-08-1988
		EP 0280999 A	07-09-1988
		HK 59496 A	12-04-1996
		IE 60931 B	07-09-1994
		JP 2619904 B	11-06-1997
		JP 63225322 A	20-09-1988
		PH 26279 A	10-04-1992
US 4793998 A	27-12-1988	AT 65915 T	15-08-1991
		AU 614710 B	05-09-1991
		AU 7927487 A	28-04-1988
		CA 1297023 A	10-03-1992
		DE 3772001 A	12-09-1991
		DK 543687 A	21-04-1988
		EP 0264888 A	27-04-1988
		FI 874593 A,B,	21-04-1988
		GR 3002454 T	30-12-1992
		HK 85394 A	26-08-1994
		IE 61436 B	02-11-1994
		JP 2852043 B	27-01-1999
		JP 63104930 A	10-05-1988
		KR 9600431 B	06-01-1996
		NO 174765 B	28-03-1994
		PH 25502 A	24-07-1991
		PT 85941 A,B	01-11-1987
		SG 90194 G	14-10-1994
US 4830853 A	16-05-1989	AT 67090 T	15-09-1991
		AU 604061 B	06-12-1990
		AU 7939787 A	21-04-1988
		CA 1297024 A	10-03-1992
		DE 3772924 A	17-10-1991
		DK 543587 A	21-04-1988
		EP 0264887 A	27-04-1988
		FI 874594 A	21-04-1988
		GR 3002698 T	25-01-1993
		HK 85694 A	26-08-1994
		IE 60773 B	10-08-1994
		JP 2703906 B	26-01-1998
		JP 63104931 A	10-05-1988
		KR 9600430 B	06-01-1996
		PH 25582 A	08-08-1991
		PT 85942 A,B	01-11-1987
		SG 95494 G	28-10-1994
EP 0468929 A	29-01-1992	AT 400519 B	25-01-1996
		AT 147691 A	15-06-1995
		AU 639354 B	22-07-1993
		AU 8128691 A	30-01-1992
		CA 2047802 A	26-01-1992
		CH 683150 A	31-01-1994
		CS 9102309 A	15-04-1992
		DE 4124409 A	30-01-1992

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International Application No

PCT/US 99/10189

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0468929 A		DK 468929 T	27-12-1994
		ES 2061218 T	01-12-1994
		FI 913554 A,B,	26-01-1992
		GB 2246296 A,B	29-01-1992
		IE 66184 B	13-12-1995
		IL 98934 A	23-07-1996
		IT RM910554 A	27-01-1992
		JP 2502849 B	29-05-1996
		JP 4253923 A	09-09-1992
		LU 87980 A	15-02-1993
		PL 167712 B	31-10-1995
		PT 98417 A,B	30-06-1992
		SK 278563 B	08-10-1997
		RU 2075310 C	20-03-1997

---